PT Darya-Varia Laboratoria Tbk (DVLA.JK)
IDR 1600.0
(-1.23%)
IDR 1600.0
(-1.23%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 639.05 Billion IDR | 5.54% |
| 2022 | 605.51 Billion IDR | -14.12% |
| 2021 | 705.1 Billion IDR | 6.77% |
| 2020 | 660.42 Billion IDR | 26.06% |
| 2019 | 523.88 Billion IDR | 8.56% |
| 2018 | 482.55 Billion IDR | -8.01% |
| 2017 | 524.58 Billion IDR | 16.11% |
| 2016 | 451.78 Billion IDR | 12.17% |
| 2015 | 402.76 Billion IDR | 47.09% |
| 2014 | 273.81 Billion IDR | -0.56% |
| 2013 | 275.35 Billion IDR | 18.1% |
| 2012 | 233.14 Billion IDR | 16.36% |
| 2011 | 200.37 Billion IDR | -6.15% |
| 2010 | 213.5 Billion IDR | -6.64% |
| 2009 | 228.69 Billion IDR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 774.11 Billion IDR | -0.54% |
| 2024 Q1 | 731.66 Billion IDR | 14.49% |
| 2024 Q2 | 778.29 Billion IDR | 6.37% |
| 2023 Q4 | 639.05 Billion IDR | 7.51% |
| 2023 Q1 | 595.73 Billion IDR | -1.62% |
| 2023 Q2 | 602.13 Billion IDR | 1.07% |
| 2023 FY | 639.05 Billion IDR | 5.54% |
| 2023 Q3 | 594.43 Billion IDR | -1.28% |
| 2022 Q1 | 673.86 Billion IDR | -4.43% |
| 2022 Q2 | 596.69 Billion IDR | -11.45% |
| 2022 Q3 | 622.21 Billion IDR | 4.28% |
| 2022 Q4 | 605.51 Billion IDR | -2.68% |
| 2022 FY | 605.51 Billion IDR | -14.12% |
| 2021 Q1 | 628.46 Billion IDR | -4.84% |
| 2021 Q4 | 705.1 Billion IDR | 3.78% |
| 2021 Q3 | 679.41 Billion IDR | 8.16% |
| 2021 Q2 | 628.14 Billion IDR | -0.05% |
| 2021 FY | 705.1 Billion IDR | 6.77% |
| 2020 Q4 | 660.42 Billion IDR | 19.31% |
| 2020 Q1 | 588.49 Billion IDR | 12.33% |
| 2020 Q2 | 582.04 Billion IDR | -1.1% |
| 2020 FY | 660.42 Billion IDR | 26.06% |
| 2020 Q3 | 553.52 Billion IDR | -4.9% |
| 2019 FY | 523.88 Billion IDR | 8.56% |
| 2019 Q2 | 592.35 Billion IDR | 10.76% |
| 2019 Q4 | 523.88 Billion IDR | -6.75% |
| 2019 Q1 | 534.81 Billion IDR | 10.83% |
| 2019 Q3 | 561.8 Billion IDR | -5.16% |
| 2018 Q3 | 492.8 Billion IDR | -3.42% |
| 2018 Q2 | 510.23 Billion IDR | -7.45% |
| 2018 FY | 482.55 Billion IDR | -8.01% |
| 2018 Q1 | 551.33 Billion IDR | 5.1% |
| 2018 Q4 | 482.55 Billion IDR | -2.08% |
| 2017 Q1 | 559.28 Billion IDR | 23.79% |
| 2017 Q2 | 535.92 Billion IDR | -4.18% |
| 2017 Q3 | 488.55 Billion IDR | -8.84% |
| 2017 Q4 | 524.58 Billion IDR | 7.37% |
| 2017 FY | 524.58 Billion IDR | 16.11% |
| 2016 FY | 451.78 Billion IDR | 12.17% |
| 2016 Q4 | 451.78 Billion IDR | -9.75% |
| 2016 Q2 | 469.15 Billion IDR | 1.1% |
| 2016 Q3 | 500.6 Billion IDR | 6.7% |
| 2016 Q1 | 464.07 Billion IDR | 15.22% |
| 2015 Q3 | 459.88 Billion IDR | -2.38% |
| 2015 FY | 402.76 Billion IDR | 47.09% |
| 2015 Q4 | 402.76 Billion IDR | -12.42% |
| 2015 Q1 | 332.35 Billion IDR | 21.38% |
| 2015 Q2 | 471.1 Billion IDR | 41.75% |
| 2014 Q1 | 220.4 Billion IDR | -19.95% |
| 2014 Q3 | 296.51 Billion IDR | 51.92% |
| 2014 Q4 | 273.81 Billion IDR | -7.65% |
| 2014 Q2 | 195.17 Billion IDR | -11.45% |
| 2014 FY | 273.81 Billion IDR | -0.56% |
| 2013 Q2 | 268.26 Billion IDR | 43.05% |
| 2013 Q3 | 208.33 Billion IDR | -22.34% |
| 2013 Q4 | 275.35 Billion IDR | 32.17% |
| 2013 FY | 275.35 Billion IDR | 18.1% |
| 2013 Q1 | 187.52 Billion IDR | -2.18% |
| 2012 Q4 | 191.71 Billion IDR | -3.22% |
| 2012 FY | 233.14 Billion IDR | 16.36% |
| 2012 Q3 | 198.1 Billion IDR | 0.0% |
| 2011 FY | 200.37 Billion IDR | -6.15% |
| 2010 FY | 213.5 Billion IDR | -6.64% |
| 2009 FY | 228.69 Billion IDR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| PT Merck Tbk | 161.93 Billion IDR | -294.635% |
| PT Phapros, Tbk | 995.56 Billion IDR | 35.81% |
| PT Pyridam Farma Tbk | 1164.17 Billion IDR | 45.107% |
| PT Industri Jamu dan Farmasi Sido Muncul Tbk | 504.76 Billion IDR | -26.604% |
| PT Tempo Scan Pacific Tbk | 3250.09 Billion IDR | 80.337% |